Dementia Consortium Signs Additional Partner

Abbvie has become a pharmaceutical partner of the Dementia Consortium, joining medical research charity MRC Technology, Alzheimer’s Research UK and pharmaceutical companies Astex, Eisai and Lilly. 

The Consortium, a global £4m collaboration between academia, charity and the private sector uses its combined expertise to drive early stage drug discovery programmes against promising academic targets for neurodegenerative disease.

 Dr Jim Summers, Vice-President of Neuroscience Discovery Research at AbbVie said: “We are pleased to be part of the Dementia Consortium. This innovative approach to validating new drug targets is an important component of our strategy to develop new therapies to treat neurodegenerative diseases.”

Dr Simon Ridley, Director of Research at Alzheimer’s Research UK, said: “It’s a very positive development to have AbbVie join the Dementia Consortium, strengthening our ability to accelerate the search for effective new treatments for dementia. We know that in order to find new treatments for neurodegenerative diseases, we need to explore as many different approaches as possible, and our growing range of Pharma partnerships will ensure we can continue to invest in a diverse range of projects to build drug discovery pipelines.”

 To date, the Consortium has awarded over £1.5m to early stage drug discovery efforts for neurodegenerative diseases, including projects that target the immune system in a bid to halt nerve cell damage in Alzheimer’s and a project studying targeting TDP-43 aggregation in frontotemporal dementia and amyotrophic lateral sclerosis (ALS).

For further information about the consortium please visit https://ilmt.co/PL/k3Rd.